Save 20% on your order with code
K4 Elite logo K4 Elite
Home / Peptide Library / NA-Selank Amidate
Limited Research

NA-Selank Amidate

Cognitive & Neurological · N-Acetyl Selank Amidate, NA-Selank, acetylated Selank analogue

NA-Selank Amidate is a chemically modified analogue of Selank, a synthetic tuftsin-derived heptapeptide, carrying an N-terminal acetyl group and a C-terminal amide; the published research base concerns the parent peptide Selank rather than the modified analogue itself.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Research Level
Limited Research
Browse the store →
🧬

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia, built from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with a Pro-Gly-Pro stabilising sequence. NA-Selank Amidate is a further-modified analogue in which the N-terminus is acetylated and the C-terminus is amidated.

Terminal acetylation and amidation are standard peptide-chemistry strategies for reducing exopeptidase susceptibility, since they remove the free amine and free carboxylate that amino- and carboxypeptidases recognise. The same modification pattern is used in NA-Semax Amidate relative to Semax.

An important caveat for anyone using this entry: essentially all peer-reviewed pharmacology cited below was generated with Selank, not with the acetylated-amidated analogue. Direct comparative studies of NA-Selank Amidate are not established in the indexed literature, and the status is recorded here as limited research on that basis.

The Selank literature describes several reported mechanisms in rodent and cell models: modulation of GABA-A receptor-linked signalling and of gene expression relating to GABAergic neurotransmission, changes in monoamine turnover (including reported increases in the ratio of 5-hydroxyindoleacetic acid to serotonin in hypothalamus and striatum, interpreted as accelerated serotonin turnover), and effects on enkephalin-degrading enzyme activity in plasma.

Neurotrophic signalling is a second reported axis. Following intranasal administration in rats, investigators reported increases in hippocampal BDNF messenger RNA within roughly three hours and BDNF protein within about twenty-four hours, alongside differential expression of genes associated with neuronal plasticity and inflammation. Whether the acetylated and amidated analogue reproduces these findings has not been established in the published literature.

  • Neurotrophic gene expression. Hippocampal BDNF and NGF messenger RNA and protein following intranasal administration in rats [1][3].
  • GABAergic signalling. Expression of genes involved in GABAergic neurotransmission in cell models, and reported GABA-A receptor-linked modulation [2].
  • Monoamine turnover. Serotonin and 5-HIAA measurements in rodent hypothalamus and striatum [3].
  • Behavioural paradigms. Open-field, elevated plus maze and Morris water maze work with the parent peptide in rodents [3].
  • Peptide stability chemistry. General literature on N-terminal acetylation and C-terminal amidation as exopeptidase-resistance strategies [4].
  • Tuftsin-derived peptide immunology. Background literature on the tuftsin parent sequence.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Intranasal Selank and hippocampal BDNF (rat). Species/model: adult rats. Route as studied: intranasal. Measure: hippocampal BDNF messenger RNA and protein, plus transcriptome-wide expression. Reported outcome: BDNF messenger RNA increased within approximately 3 hours and BDNF protein within approximately 24 hours after a single administration, with differential expression of genes linked to neuronal plasticity and inflammation [1][3].

GABAergic gene expression in cell culture. Model: IMR-32 human neuroblastoma cells. Measure: expression of genes involved in GABAergic neurotransmission, with GABA and olanzapine as comparators. Reported outcome: Selank altered expression of genes in this pathway in the reported conditions [2].

Rodent behavioural and neurochemical characterisation. Species/model: laboratory rodents. Measures: open-field activity, elevated plus maze, Morris water maze, and regional monoamine and metabolite concentrations. Reported outcome: an anxiolytic-type behavioural phenotype with increased 5-HIAA to serotonin ratios in hypothalamus and striatum, interpreted by the authors as accelerated serotonin turnover rather than raised absolute serotonin [3].

Evidence caveat. All four bodies of work above used Selank. No peer-reviewed head-to-head comparison of NA-Selank Amidate against Selank on these endpoints was located during compilation of this entry. Terminal-modification effects on potency, half-life and brain exposure should be treated as unresolved [4].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

SelankCaution
The unmodified parent peptide; running both in the same system prevents attribution of any observed effect to the terminal modifications.
NA-Semax AmidateCompatible
A separately studied modified Russian peptide; often examined in parallel in nootropic-peptide research, with distinct primary mechanisms.
GABA-A receptor ligands (e.g. benzodiazepine research compounds)Caution
Overlapping GABAergic pathway engagement is reported for Selank; combined use confounds mechanistic interpretation.
SemaxCompatible
Different parent sequence (ACTH(4-7) derived) and different reported primary mechanism; frequently studied alongside Selank.
  1. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008.
  2. GABA, Selank and olanzapine affect expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol.
  3. Selank and monoamine turnover / behavioural characterisation - Kozlovskaya and Semenova group reports, Institute of Molecular Genetics.
  4. PubChem compound search - Selank and related analogues.
What is NA-Selank Amidate?
A modified analogue of Selank carrying an N-terminal acetyl group and a C-terminal amide. Selank itself is a synthetic heptapeptide derived from the tetrapeptide tuftsin extended with a Pro-Gly-Pro sequence.
Why acetylate and amidate the termini?
Removing the free N-terminal amine and free C-terminal carboxylate reduces recognition by amino- and carboxypeptidases, a standard peptide-chemistry approach to slowing enzymatic degradation.
Does the research on Selank apply to this analogue?
Not automatically. The indexed literature almost entirely concerns Selank. No established head-to-head comparison of the acetylated-amidated analogue was located, so potency, exposure and half-life differences should be treated as unresolved.
What is tuftsin?
A naturally occurring immunomodulatory tetrapeptide, Thr-Lys-Pro-Arg, derived from the IgG heavy chain; it is the structural basis of the Selank sequence.
Is this product intended for human use?
No. This material is supplied for laboratory research use only. It is not a drug, dietary supplement or medical device, and it is not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.